{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:21:10Z","timestamp":1789154470259,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,6]]},"DOI":"10.7759\/cureus.80136","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:54:02Z","timestamp":1741262042000},"source":"Crossref","is-referenced-by-count":3,"title":["Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis"],"prefix":"10.7759","author":[{"given":"Liyan","family":"Mazahreh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Mazahreh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan","family":"Alqtishat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazin","family":"Safar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan WM","year":"2010","unstructured":"Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010, 7:277-85. 10.1038\/nrurol.2010.47","journal-title":"Nat Rev Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain L","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016, 44:51-60. 10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"ref5","article-title":"Immune checkpoint inhibitor therapy in patients with autoimmune disease","volume":"32","author":"Johnson DB","year":"2018","unstructured":"Johnson DB, Beckermann KE, Wang DY. Immune checkpoint inhibitor therapy in patients with autoimmune disease. Oncology (Williston Park). 2018, 32:190-4.","journal-title":"Oncology (Williston Park)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri TK","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, et al.. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015, 373:1814-23. 10.1056\/NEJMoa1510016","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer RJ","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, et al.. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015, 33:1430-7. 10.1200\/JCO.2014.59.0703","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01785","article-title":"Immunopathogenesis in myasthenia gravis and neuromyelitis optica","volume":"8","author":"Wang Z","year":"2017","unstructured":"Wang Z, Yan Y. Immunopathogenesis in myasthenia gravis and neuromyelitis optica. Front Immunol. 2017, 8:1785. 10.3389\/fimmu.2017.01785","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian SL","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016, 16:275-87. 10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017, 377:1345-56. 10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336931-tumor-response-to-immune-oncology-therapy-despite-high-dose-steroid-intervention-in-a-patient-with-papillary-renal-cell-carcinoma-and-immune-related-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:54:03Z","timestamp":1741262043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336931-tumor-response-to-immune-oncology-therapy-despite-high-dose-steroid-intervention-in-a-patient-with-papillary-renal-cell-carcinoma-and-immune-related-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.80136","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}